{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:09:54Z","timestamp":1789380594697,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the incidence and prognostic significance of imaging-detected immune-related adverse events (irAEs) in patients with unresectable biliary tract cancer (BTC) receiving durvalumab combined with gemcitabine and cisplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 66 patients (mean age \u00b1 standard deviation, 64.7\u2009\u00b1\u20099.4 years, 35 women) with histologically confirmed unresectable BTC who received a combination of durvalumab, gemcitabine, and cisplatin as the first-line systemic therapy. Clinical records and imaging studies were reviewed to identify irAEs. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), treatment response, and incidence of irAEs. Cox regression analyses were conducted to determine predictors of survival outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Imaging-detected irAEs were observed in 21.2% (14\/66) of patients, with the most frequent findings being bowel wall thickening and transient inflammatory lung nodules. The majority of these events (85.7%) manifested within 90 days of treatment initiation, and only 35.7% (5\/14) had clinical symptoms related to irAE. In multivariate analysis, the presence of imaging-detected irAEs was a significant independent predictor of improved OS (hazard ratio (HR) = 0.42;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017) and PFS (HR\u2009=\u20090.43;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.016). The median OS was significantly longer in patients with imaging-detected irAEs compared to those without (23.0 vs. 12.0 months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Imaging-detected irAEs are potent prognostic markers for superior survival in BTC patients receiving durvalumab-based chemotherapy. Given that these events are frequently subclinical and occur early in the treatment course, meticulous radiologic surveillance is essential to identify patients likely to achieve favorable clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The relationship between immune-related adverse events (irAEs) on imaging and treatment outcome in biliary tract cancer patients undergoing durvalumab-based therapy has not been thoroughly investigated.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>The development of irAEs detected on imaging study was significantly associated with improved overall survival.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Careful imaging evaluation during follow-up to detect early irAE-related change is important, since the occurrence of irAEs may indicate better clinical outcomes.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12645-x","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:03:35Z","timestamp":1779984215000},"page":"8012-8020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of imaging-detected immune-related adverse events in biliary tract cancer patients receiving durvalumab-based chemotherapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Jeongin","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8983-851X","authenticated-orcid":false,"given":"Dong Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Rae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Hyun","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"12645_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-13605-3","volume":"12","author":"MJ Kang","year":"2022","unstructured":"Kang MJ, Lim J, Han S-S et al (2022) Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study. Sci Rep 12:10206","journal-title":"Sci Rep"},{"key":"12645_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/ags3.12710","volume":"7","author":"I Endo","year":"2023","unstructured":"Endo I (2023) Recent progress in the treatment for unresectable biliary tract cancer. Ann Gastroenterol Surg 7:540\u2013542","journal-title":"Ann Gastroenterol Surg"},{"key":"12645_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J et al (2023) Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 34:127\u2013140","journal-title":"Ann Oncol"},{"key":"12645_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1:EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"12645_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865","journal-title":"Lancet"},{"key":"12645_CR6","unstructured":"National Comprehensive Cancer Network\u00ae (2025) NCCN clinical practice guidelines in oncology biliary tract cancers version 1.2025. Available via nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf. Accessed 9 Apr 2025"},{"key":"12645_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA et al (2015) Identification and characterization of MEDI4736, an antagonistic Anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3:1052\u20131062","journal-title":"Cancer Immunol Res"},{"key":"12645_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","volume":"72","author":"B Sangro","year":"2020","unstructured":"Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR (2020) Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol 72:320\u2013341","journal-title":"J Hepatol"},{"key":"12645_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1133207","volume":"14","author":"AM Berz","year":"2023","unstructured":"Berz AM, Boughdad S, Vietti-Violi N et al (2023) Imaging assessment of toxicity related to immune checkpoint inhibitors. Front Immunol 14:1133207","journal-title":"Front Immunol"},{"key":"12645_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","volume":"132","author":"D Maillet","year":"2020","unstructured":"Maillet D, Corbaux P, Stelmes J-J et al (2020) Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer 132:61\u201370","journal-title":"Eur J Cancer"},{"key":"12645_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","volume":"7","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Lee K-H, Lee D-W et al (2022) Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol 7:522\u2013532","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12645_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 4:374\u2013378","journal-title":"JAMA Oncol"},{"key":"12645_CR13","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41416-024-02662-2","volume":"130","author":"K Haratani","year":"2024","unstructured":"Haratani K, Nakamura A, Mamesaya N et al (2024) Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer. Br J Cancer 130:1783\u20131794","journal-title":"Br J Cancer"},{"key":"12645_CR14","doi-asserted-by":"publisher","first-page":"W992","DOI":"10.2214\/AJR.10.6198","volume":"197","author":"Y Bronstein","year":"2011","unstructured":"Bronstein Y, Ng CS, Hwu P, Hwu WJ (2011) Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 197:W992\u2013W1000","journal-title":"AJR Am J Roentgenol"},{"key":"12645_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2214\/AJR.21.26538","volume":"218","author":"S Sheikhbahaei","year":"2022","unstructured":"Sheikhbahaei S, Marcus CV, Sadaghiani MS, Rowe SP, Pomper MG, Solnes LB (2022) Imaging of cancer immunotherapy: response assessment methods, atypical response patterns, and immune-related adverse events, from the AJR Special Series on Imaging of Inflammation. AJR Am J Roentgenol 218:940\u2013952","journal-title":"AJR Am J Roentgenol"},{"key":"12645_CR16","doi-asserted-by":"crossref","unstructured":"Cherk MH, Nadebaum DP, Barber TW, Beech P, Haydon A, Yap KS (2022) 18F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy. J Med Imaging Radiat Oncol 66:483\u2013494","DOI":"10.1111\/1754-9485.13390"},{"key":"12645_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","volume":"132","author":"B Jayathilaka","year":"2025","unstructured":"Jayathilaka B, Mian F, Franchini F, Au-Yeung G, Ijzerman M (2025) Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer 132:51\u201357","journal-title":"Br J Cancer"},{"key":"12645_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580","journal-title":"Nat Rev Clin Oncol"},{"key":"12645_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1026964","volume":"13","author":"A Dey","year":"2022","unstructured":"Dey A, Austin M, Kluger HM et al (2022) Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. Front Immunol 13:1026964","journal-title":"Front Immunol"},{"key":"12645_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Prim 6:38","journal-title":"Nat Rev Dis Prim"},{"key":"12645_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104494","volume":"10","author":"A Rios-Hoyo","year":"2025","unstructured":"Rios-Hoyo A, Dai J, Noel T, Blenman KRM, Park T, Pusztai L (2025) Immune-related adverse events are associated with better event-free survival in a phase I\/II clinical trial of durvalumab concomitant with neoadjuvant chemotherapy in early-stage triple-negative breast cancer. ESMO Open 10:104494","journal-title":"ESMO Open"},{"key":"12645_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07142-3","volume":"20","author":"H Matsuoka","year":"2020","unstructured":"Matsuoka H, Hayashi T, Takigami K et al (2020) Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer 20:656","journal-title":"BMC Cancer"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12645-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12645-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T09:53:37Z","timestamp":1789379617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12645-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["12645"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12645-x","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Dong Ho Lee.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No complex statistical methods were necessary for this paper.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}